BiOrion Technologies announced today that a first fibrosis patient has been enrolled in the first-in-human PET imaging study with 68-Gallium labeled PDGF beta receptor binding bicyclic peptide BOT5035.
Herman Steen, CEO of BiOrion, “The enrollment of the first patient in this PET imaging study is a significant milestone for BiOrion. As the PDGF beta receptor represents a specific biomarker for activated myofibroblasts, it is expected to be a sensitive biomarker for fibrosis activity and therefore for disease monitoring of fibrotic diseases”. “This study will allow us to generate insight in the potential of this receptor for disease monitoring of other fibrotic diseases including cancers with fibrotic stroma, such as colon cancer”.
About BiOrion Technologies
BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion PET-imaging diagnostics for fibrotic diseases. These diseases include cardiac, hepatic, pulmonary and kidney fibrosis, among many others, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding peptides and single domain antibodies that act as targeting vehicles for diagnostic PET radionuclides, therapeutic radionuclides and (existing) anti-fibrotic therapeutics.
For BiOrion Technologies BV:
Herman Steen, PhD
CEO BiOrion Technologies BV